The Latest
-
Stock via Getty Images
As gene therapies falter on the market, this biopharma is aiming to defy the odds
After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.
-
Permission granted by AstraZeneca
Q&AInside AstraZeneca’s long-game strategy in lung cancer
New long-term results for Tagrisso in EGFR-mutated non-small cell lung cancer showcase a precision approach the company has honed for decades.
-
Andrew Harnik via Getty Images
PBM reform was dropped from Trump’s spending bill. It could have saved billions.
The Senate nixed a provision to “delink” drug list prices from compensation for PBMs and other drug middlemen days before its passage.
-
Chip Somodevilla / Staff via Getty Images
Let’s make a deal? Big Pharma execs express varying views on their M&A future
Pharma executives are keeping their eyes open for dealmaking opportunities as every company has its own battles to fight.
-
Permission granted by Vertex Pharmaceuticals
David Altshuler, geneticist who helped transform Vertex, to retire next year
Since becoming Vertex's top scientist in 2015, Altshuler has helped the company become an industry powerhouse. He’ll depart next year in a “planned transition.”
-
stock via Getty Images
Drugmakers score policy win in a prolonged fight against 340B
A new pilot program from HHS would alter the contentious 340B pricing program by swapping traditional upfront drug discounts for rebates.
-
Courtesy of Merck & Co.
Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus
With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater understanding of its drivers.
-
Permission granted by Novo Nordisk
C-suite shuffles ripple through pharma
Novo Nordisk, Kenvue and Jazz Pharmaceuticals announced changes at the top this month.
-
Permission granted by Roche
Roche pushes ahead with late-comer strategy in obesity
The Swiss pharma company announced several updates to its obesity portfolio in its latest earnings report.
-
Retrieved from Vinay Prasad on May 08, 2025
Dr. Vinay Prasad, controversial FDA official, abruptly departs agency
Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office got embroiled in controversy over a Duchenne gene therapy.
-
Stock via Getty Images
Biotech investing is down, but some VC firms are bucking the trend
Discipline is the name of the game after a glut of over-investing burst the biotech bubble.
-
Permission granted by Merck & Co.
Could bispecifics unseat Keytruda from its oncology throne?
Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.
-
E+ via Getty Images
From the bench: Researchers make NIH-funded preclinical strides in mRNA and obesity
The studies are contributing preclinical advances for some of the world’s biggest blockbusters.
-
Stock via Getty Images
Pharma’s turbo spending spree on US manufacturing
The industry’s push to expand American drug production isn’t abating as threats of tariffs loom.
-
Courtesy of BMS
How Bristol Myers Squibb uses AI to validate drugs before they’re even in the lab
The company’s AI approach allows molecule candidates to be vetted for efficacy and other properties early in development.
-
Mario Guti via Getty Images
Who is Dr. George Tidmarsh, the new director of CDER?
Despite past criticism of public health policies, Tidmarsh recently praised the FDA and said he’ll focus on boosting review efficiencies.
-
Sedat Suna via Getty Images
Novartis’ Zolgensma sales fall again as gene therapy market woes persist
Novartis has seen sales decline in a difficult gene therapy market. Is there hope on the horizon?
-
Mario Tama via Getty Images
3 major patent losses this year — and a key strategy to fill the gaps
Despite promising pipelines, most new launches are missing sales targets, forcing pharmas to rethink sales strategies.
-
Stock via Getty Images
Why FDA’s CRL release could open the door to lawsuits against pharma
In a push for “radical transparency” the FDA released 200 CRLs for drugs that were later approved — some of which are now public for the first time.
-
Mario Tama / Staff via Getty Images
J&J accelerates past Stelara’s fall with better-than-expected portfolio growth
Stelara is faltering due to biosimilar entries, but J&J execs demonstrate they were ready to fill the gap all along.
-
Stock via Getty Images
FDA invites more data from abroad — with a wary eye on China
The FDA approved four drugs last year without any U.S. trial participants, but has maintained a tougher stance on China, even as it grows into an R&D powerhouse.
-
Michael M. Santiago via Getty Images
Biotech IPO momentum gained steam last year, but market ‘turmoil’ has slowed the train again
The IPO market is a mixed bag in 2025, with some signs of life but several headwinds keeping activity relatively low.
-
Stock via Getty Images
Q&ANeed a DTC platform? Here’s how one company built its own.
Currax Pharmaceuticals was ahead of the curve when it set up a direct access platform for its obesity med.
-
Jason Doiy via Getty Images
With Verona deal, Merck wagers on strength of lung drug’s patents
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make good on the deal, other secondary patents will need to hold up.
-
Jan Sonnenmair via Getty Images
Early measles drug R&D kicks into gear as U.S. records record outbreak
Several companies have announced preclinical efforts to develop the first-ever measles treatment.
